As part of Myriad’s ongoing commitment to advance the science of lung cancer care, we shared exciting new data at this year’s AACR-IASLC International Joint Conference in San Diego. Here is a quick recap of the poster presentation targeted at improving patient outcomes in early stage lung cancer.
Recurrence and lung cancer mortality in resected, early stage non-small cell lung cancer (NSCLC) are likely due to the presence of micro-metastatic disease not detected during surgery or the pre-surgical assessment. The aim of this study was to validate cell cycle progression gene expression (CCP Score) and the molecular Prognostic Score as predictors of 5-year distant recurrence-free survival in a cohort of surgically treated lung adenocarcinomas without adjuvant treatment.
The CCP score and the molecular prognostic score are independent prognostic markers of 5-year distant recurrence in patients with early stage lung adenocarcinoma treated with surgery, independent of age, tumor size and pleural invasion.
The prediction of risk of distant recurrence in resected lung adenocarcinoma patients can be improved over that obtained by the current standard of pathological stage by incorporating tumor expression of proliferation markers (CCP score).
Improved risk stratification can help identify patients in need of additional treatment and prioritize patients for trials of emerging new therapies.
Guide your discussions with patients on hereditary cancer syndromes.